Prediabetes and GLP-1: What You Need to Know

GLP-1 and Prediabetes: The Mechanism

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally produces after you eat. It belongs to a class of hormones called incretins, which kick into action whenever food enters your digestive system.

Once released, GLP-1 does several things at once. It stimulates your pancreas to release insulin in a glucose-dependent manner, meaning it only works when your blood sugar is actually elevated. It suppresses glucagon, the hormone that tells your liver to release stored glucose. It slows down gastric emptying, which keeps you feeling full longer and steadies the rate at which sugar enters your bloodstream. And it acts on brain regions that control appetite, making you naturally eat less without having to white-knuckle your way through willpower battles.

GLP-1 receptors are found in the pancreas, brain, heart, kidneys, and gastrointestinal tract, which explains why the effects of these medications extend beyond just blood sugar. The GLP-1 analogs available by prescription, such as semaglutide, liraglutide, and dulaglutide, are engineered versions of this natural hormone. They resist rapid breakdown by an enzyme called DPP-4, which gives them a much longer half-life and allows for once-daily or once-weekly dosing instead of multiple daily injections.

Clinical Evidence: Does GLP-1 Work in Prediabetes?

The evidence here is more solid than many people realize. This is not theoretical or experimental territory.

The SCALE Prediabetes trial, published in Obesity by Pi-Sunyer and colleagues in 2015, tested liraglutide at 3.0 milligrams per day in people with prediabetes and obesity. Over 160 weeks, participants who received the medication were 80 percent less likely to progress to type 2 diabetes compared with those on placebo. Mean body weight dropped by 6.1 percent in the liraglutide group.

Semaglutide has shown similarly impressive results. A study led by Wadden and published in JAMA in 2020 looked at weekly subcutaneous semaglutide at 2.4 milligrams in adults with overweight or obesity. After 68 weeks, the medication reduced prediabetes prevalence by 58 percent, with many participants reverting to normal blood sugar levels. The STEP 1 trial, published in the New England Journal of Medicine by Wilding and colleagues in 2021, confirmed these findings, showing a 73 percent reversal of prediabetes classification at 68 weeks in participants receiving semaglutide.

A systematic review and meta-analysis in the Lancet Diabetes and Endocrinology journal by Dee and collaborators (2023) pooled data across multiple trials and found that GLP-1 analogs reduced the risk of developing type 2 diabetes by 35 percent in prediabetes populations, independent of weight loss. That last part is important. Even if the scale does not move much, the medication appears to improve metabolic function through mechanisms beyond just appetite suppression.

Additional data from Newman and colleagues, published in the New England Journal of Medicine in 2023, showed that semaglutide improved liver histology in people with metabolic dysfunction-associated steatohepatitis, a condition closely tied to insulin resistance. Cardiovascular outcome trials such as SUSTAIN-6 and LEADER also demonstrated significant reductions in major adverse cardiovascular events in high-risk populations, which matters because people with prediabetes often carry cardiovascular risk alongside their blood sugar issues.

GLP-1 vs. Metformin in Prediabetes

Metformin has been around for decades. It works by reducing fasting glucose production in the liver and improving insulin sensitivity in peripheral tissues. The Diabetes Prevention Program Research Group, writing in the New England Journal of Medicine in 2002, showed that metformin reduced the incidence of type 2 diabetes by approximately 30 percent in people with prediabetes. It is inexpensive, well-studied, and available in generic form.

GLP-1 medications outperform metformin on several fronts. Weight loss with GLP-1 analogs typically ranges from 5 to 10 percent of body weight, compared with 1 to 2 percent with metformin. GLP-1 medications also offer proven cardiovascular protection that metformin does not provide. Beyond blood sugar, GLP-1 improves multiple metabolic markers including blood pressure, lipids, and liver fat content.

The American Diabetes Association updated its guidelines in 2024 to recommend GLP-1 for individuals with prediabetes and a BMI of 27 kilograms per square meter or higher who also have weight-related comorbidities. The evidence supports this recommendation, though cost and access remain real-world barriers that many people have to navigate.

Who Is a Candidate for GLP-1 in Prediabetes

Not everyone with a slightly elevated HbA1c needs to be on a GLP-1 medication. The people who tend to benefit most meet a few criteria. A BMI of 30 or higher, or a BMI of 27 or higher combined with conditions like hypertension, dyslipidemia, non-alcoholic fatty liver disease, or obstructive sleep apnea, puts you in the range where the benefits of pharmacotherapy are clearly documented. Confirmed prediabetes through laboratory testing is the baseline requirement.

If you have made serious attempts at lifestyle changes without adequate results, or if you are unable or unwilling to follow intensive diet and exercise protocols, that is a legitimate reason to discuss GLP-1 with your doctor. Contraindications do exist. Personal or family history of medullary thyroid carcinoma, MEN2 syndrome, chronic pancreatitis, or current pregnancy are all reasons to avoid these medications or pursue them only under very specific specialist supervision.

The Role of Continuous Monitoring During GLP-1 Treatment

Starting a GLP-1 medication is not a set-it-and-forget-it decision. The treatment requires ongoing attention, and the people who get the best results are the ones who track their data consistently.

Blood glucose and HbA1c monitoring tells you whether the medication is actually working to lower your blood sugar. Weight tracking matters because losing 5 to 10 percent of your body weight reduces progression risk, as shown in the Diabetes Prevention Program study led by Knowler and colleagues, published in the New England Journal of Medicine in 2002. Logging symptoms and adverse events is equally important during the first few months, when side effects like nausea, diarrhea, and constipation are most common. Knowing when those symptoms started, how long they lasted, and what seemed to help gives your doctor useful information for adjusting your protocol.

Laboratory follow-up with a lipid panel, liver function tests, and insulin measurements rounds out the picture. All of this data, gathered over weeks and months, tells a story that a single snapshot in time cannot.

That is exactly what PeptPro was built for. You can log your blood glucose readings, weight measurements, medication doses, and symptoms in one place, building a complete history that makes your appointments more productive. When you walk into a consultation with months of data in charts and organized records, you and your doctor spend less time reconstructing the past and more time making decisions about what comes next. Get started here and see how tracking everything in one spot changes the conversation.

People who keep a log of their symptoms and bring it to their doctor make more targeted adjustments. No one has to rely on vague recall of how they felt last month. The app lets you record what you ate, when you took your dose, and how you felt in the hours afterward, which helps identify patterns that would otherwise stay hidden.

Regular blood tests are part of the process too. Your HbA1c, lipid panel, and liver function tests need to be checked at baseline and then periodically to confirm the medication is moving the right numbers in the right direction.

Lifestyle Changes as Complement to GLP-1

GLP-1 medications do not replace healthy habits. They work best when combined with actual changes to how you live day to day.

On the food side, a Mediterranean-style eating pattern or a controlled low-carbohydrate approach both have solid evidence behind them for people with insulin resistance. Cutting back on ultra-processed foods and increasing fiber intake to at least 25 grams per day improves glycemic control and gut health. These are not extreme restrictions. Small, consistent shifts in food choices add up over months.

Exercise matters independently of weight loss. Research published in Diabetes Care by Colberg and colleagues in 2016 showed that 150 minutes per week of moderate aerobic activity plus two resistance training sessions improves insulin sensitivity even without any change in body weight. Your muscles become more efficient at pulling glucose out of the bloodstream, which directly counters the problem prediabetes represents.

Sleep is another piece that people underestimate. The CDC recommends 7 to 9 hours per night for most adults, and research published in Advances in Nutrition by St-Onge and colleagues in 2016 confirms that sleep deprivation worsens insulin resistance. If you are running on five hours a night, your body is fighting the medication's effects every single day.

Stress management is worth including here because chronic cortisol elevation raises blood glucose. You do not need to eliminate all stress, but finding sustainable ways to cope with the stress that is unavoidable matters for metabolic health.

GLP-1 helps with all of this by reducing appetite and food cravings. When you are not battling hunger constantly, it becomes genuinely easier to make better food choices and stick to an exercise routine. The medication lowers the barrier to behavior change rather than doing the work for you.

When to Consider Discontinuation or Maintenance

Some people reach a point where their HbA1c drops below 5.7 percent and stays there for at least six months without medication. That is prediabetes remission, and it is a legitimate milestone. But maintenance is a separate conversation. Research suggests that adipose tissue retains an epigenetic memory of obesity, which means the underlying tendency toward insulin resistance does not disappear just because your numbers look better for a few months. Many patients require continued medication to sustain the weight loss and glycemic improvements they achieved.

Tapering off a GLP-1 medication should be gradual. Stopping abruptly can lead to rebound hunger, weight regain, and rising blood glucose. Your doctor can help you map out a tapering schedule that reduces those risks.

The decision to continue, reduce, or stop medication is deeply individual. Cost, tolerability, how well you responded, and your long-term health goals all factor in. This is not a decision to make based on what worked for someone else online.

Common Myths to Debunk

A few misconceptions circulate widely enough that they are worth addressing directly.

GLP-1 does not cure diabetes. It controls blood sugar and can reverse prediabetes, but the underlying metabolic tendency remains. Monitoring and follow-up care do not become optional just because your numbers improved.

These medications require a medical indication and a prescription. You cannot simply decide on your own that they are right for you. A proper evaluation with your doctor, including a review of your lab work and medical history, must come first.

The medications work better alongside dietary changes, not instead of them. If you expect to eat whatever you want and still get the full benefit, you will be disappointed. The evidence is consistent on this point.

Finally, GLP-1 is not safe for everyone. Contraindications exist, and a doctor who knows your full medical picture is the only person qualified to determine whether the benefits outweigh the risks in your specific situation.

What Comes Next

Prediabetes is a warning sign, not a sentence. It is one of the few conditions in medicine where catching it early gives you a genuine chance to turn things around before permanent damage occurs. GLP-1 is currently the most effective pharmacological tool available for that reversal, supported by data from large randomized trials and years of clinical use.

What you do with that information matters. Schedule the follow-up blood test your doctor ordered. Track your weight and blood glucose between visits. Review your eating patterns and see where you can make one or two realistic changes. The combination of medication and consistent self-tracking gives you the clearest picture of whether the protocol is working.

PeptPro puts all of that information together in one app. Your blood glucose log, weight history, dose records, and symptom notes are organized and charted so the data tells a coherent story at every appointment. Check it out here and start building the record that makes your next consultation count.

The window for intervention is open. The best time to step through it is now.

References

• EMA — Ozempic (semaglutida), EPAR
• Wilding et al., STEP 1 — NEJM (2021)
• Lincoff et al., SELECT — NEJM (2023)